Home
    • Plans Blog Contact
    Gilead Sciences Inc logo

    Gilead Sciences Inc

    GILD
    Last price US$130.17
    Market cap US$161.9b
    12M price change 15.00%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Merck & Company IncMRK Industry peer Eli Lilly and CompanyLLY Industry peer Amgen IncAMGN Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Gilead Sciences Inc Overview

    Industry: Drug Manufacturers General

    Sector: Healthcare

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla pro Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Gilead Sciences Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $7B (+4% YoY); EPS was $2.03 (reported).

    Revenue $7B +4% YoY
    EPS $2.03 reported
    Operating income $0M reported
    Net income $2B +54% YoY

    What changed

    • Revenue +4% YoY to $7B; EPS reported to $2.03.
    • Net income +54% YoY to $2B.

    Capital return

    Dividend declared at $0.82/share.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 10-Q May 07, 2026 SEC filing FORM 8-K May 07, 2026 SEC filing FORM 10-K Feb 24, 2026 SEC filing FORM 8-K Feb 10, 2026 Earnings release EXHIBIT 99.1 Feb 10, 2026 SEC filing FORM 10-Q Nov 07, 2025 SEC filing FORM 8-K Oct 30, 2025 Earnings release EXHIBIT 99.1 Oct 30, 2025 SEC filing FORM 10-Q Aug 07, 2025 SEC filing FORM 8-K Aug 07, 2025 Earnings release EXHIBIT 99.1 Aug 07, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Gilead Sciences Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers General industry , Merck & Company Inc , Eli Lilly and Company , Amgen Inc are companies with high ratings.

    Return on Equity

    Score 2.56/5
    Gilead Sciences Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Gilead Scien... GILD US$161.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.85/5
    Gilead Sciences Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Gilead Scien... GILD US$161.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers General industry , Merck & Company Inc , Eli Lilly and Company , Amgen Inc are companies with high ratings.

    Leverage

    Score 1.74/5
    Gilead Sciences Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Gilead Scien... GILD US$161.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Gilead Sciences Inc logo

    Gilead Sciences Inc

    US$130.17

    US$115.83

    -11.0% vs price

    US$161.9b

    -3.37%

    15.00%